TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Financial Ratio Screen

NASDAQ Healthcare United States USD 599M
RATIOS FAIL*
Automated financial screen · activity assessed separately
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) is potentially non-compliant in the automated ratio model. While the debt ratio of 5.8% is acceptable, the cash and interest-bearing securities ratio of 36.2% exceeds the 30% threshold. TACTILE SYSTEMS TECHNOLOGY INC operates in the Healthcare sector.

Track TCMD screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

TCMD financial screening at a glance

RATIOS FAIL*Financial ratios shown separately from business review — not a fatwa
Debt ratio
5.8%
Pass vs 30%
Cash ratio
36.2%
Fail vs 30%
Receivables + cash
52.2%
Fail vs 30%
Impermissible income
0.9%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria not metAt least one available ratio exceeds its threshold
FTSE/Yasaar-styleFinancial criteria not metAt least one available ratio exceeds its threshold
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 5.8%
/ 30%
36.2%
/ 30%
52.2%
/ 30%
0.94%
/ 5%
RATIOS FAIL*
FTSE 5.8%
/ 33%
36.2%
/ 33%
52.2%
/ 50%
0.94%
/ 5%
RATIOS FAIL*

Financial Highlights

P/E Ratio
32.1
Forward: 17.8
EPS
$0.82
P/B Ratio
2.7
EV/EBITDA
14.6
EV: $523M
Revenue
$330M
Growth: 21.0%
Beta
1.0
Average volatility
Current Ratio
4.0

Profitability

Gross Margin 75.9%
Operating Margin 18.1%
Net Margin 5.8%
Return on Equity (ROE) 8.8%
Return on Assets (ROA) 6.4%

Cash Flow & Balance Sheet

Operating Cash Flow$43M
Free Cash Flow$40M
Total Debt$16M
Debt-to-Equity7.3
Current Ratio4.0
Total Assets$274M

Price & Trading

Last Close$26.78
50-Day MA$28.39
200-Day MA$20.05
Avg Volume351K
Beta1.0
52-Week Range
$8.61
$37.77

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-03-29 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About TACTILE SYSTEMS TECHNOLOGY INC (TCMD)

CEO
Ms. Sheri Louise Dodd
Employees
1,086
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NASDAQ
Market Cap (listing currency)
USD 599M
Currency
USD

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is TACTILE SYSTEMS TECHNOLOGY INC (TCMD) halal to invest in?

The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is TACTILE SYSTEMS TECHNOLOGY INC's debt ratio?

TACTILE SYSTEMS TECHNOLOGY INC's debt ratio is 5.8% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are TACTILE SYSTEMS TECHNOLOGY INC's key financial metrics?

TACTILE SYSTEMS TECHNOLOGY INC has a market capitalization of USD 599M in its listing currency, trailing P/E ratio of 32.1, and revenue of $330M. The company maintains a gross margin of 75.9% and a net margin of 5.8%. Return on equity stands at 8.8%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.